CR20120635A - Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10 - Google Patents
Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10Info
- Publication number
- CR20120635A CR20120635A CR20120635A CR20120635A CR20120635A CR 20120635 A CR20120635 A CR 20120635A CR 20120635 A CR20120635 A CR 20120635A CR 20120635 A CR20120635 A CR 20120635A CR 20120635 A CR20120635 A CR 20120635A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- ùtiles
- nitrògen
- hiterocyclic
- pde10 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen compuestos heterocíclicos de nitrógeno insaturados de la fórmula (I).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33452510P | 2010-05-13 | 2010-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120635A true CR20120635A (es) | 2013-01-30 |
Family
ID=44278966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120635A CR20120635A (es) | 2010-05-13 | 2012-12-13 | Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10 |
Country Status (25)
Country | Link |
---|---|
US (3) | US8957073B2 (es) |
EP (1) | EP2569300A1 (es) |
JP (1) | JP5702855B2 (es) |
KR (1) | KR101564806B1 (es) |
CN (1) | CN103221404B (es) |
AR (1) | AR081627A1 (es) |
AU (1) | AU2011253057B2 (es) |
BR (1) | BR112012029026A2 (es) |
CA (1) | CA2798490A1 (es) |
CL (1) | CL2012003178A1 (es) |
CO (1) | CO6630189A2 (es) |
CR (1) | CR20120635A (es) |
EA (1) | EA201291236A1 (es) |
IL (1) | IL222898A (es) |
MA (1) | MA34300B1 (es) |
MX (1) | MX2012013130A (es) |
NZ (1) | NZ603876A (es) |
PE (1) | PE20130576A1 (es) |
SG (1) | SG185515A1 (es) |
TN (1) | TN2012000530A1 (es) |
TW (1) | TW201206902A (es) |
UA (1) | UA109438C2 (es) |
UY (1) | UY33382A (es) |
WO (1) | WO2011143365A1 (es) |
ZA (1) | ZA201208510B (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011253143A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
MX2012013127A (es) * | 2010-05-13 | 2012-11-30 | Amgen Inc | Compuestos heteroariloxiheterociclilo como inhibidores pde10. |
KR101564806B1 (ko) * | 2010-05-13 | 2015-10-30 | 암젠 인크 | Pde10 저해제로서 유용한 질소 헤테로시클릭 화합물 |
AU2011253058A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
AU2012219316A1 (en) | 2011-02-18 | 2013-10-03 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
SG10201604682VA (en) | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
US8623860B2 (en) * | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
TW201348231A (zh) | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
US9073912B2 (en) * | 2012-05-09 | 2015-07-07 | Zoetis Services Llc | Azetidine derivatives as antiparasitic agents |
UY34858A (es) | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
CN104995182A (zh) * | 2013-02-07 | 2015-10-21 | 默克专利股份公司 | 被取代的喹喔啉衍生物及其作为mGluR4的正变构调节剂的用途 |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2015123533A1 (en) * | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyrazines modulators of gpr6 |
CN104016909B (zh) * | 2014-04-03 | 2016-04-20 | 定陶县友帮化工有限公司 | 一种2-氨基-3-溴-5-氯吡啶的合成方法 |
CN104016911A (zh) * | 2014-04-03 | 2014-09-03 | 定陶县友帮化工有限公司 | 一种2-氨基-3,5-二溴吡啶的合成方法 |
WO2015179414A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007731A1 (en) * | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
WO2016054560A1 (en) * | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
WO2017205425A1 (en) * | 2016-05-24 | 2017-11-30 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
RS63849B9 (sr) * | 2016-12-16 | 2023-06-30 | Pfizer | Agonisti glp-1 receptora i njihova upotreba |
CN110198935B (zh) | 2017-01-23 | 2022-05-31 | 卡登特治疗公司 | 钾通道调节剂 |
CN106957300A (zh) * | 2017-04-12 | 2017-07-18 | 苏州汉德创宏生化科技有限公司 | 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基)吡啶二盐酸盐的合成方法 |
EP3700935A4 (en) * | 2017-10-25 | 2021-08-04 | University Of South Florida | INGREDIENT-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM |
SI3700902T1 (sl) | 2017-10-27 | 2023-10-30 | Boehringer Ingelheim International Gmbh | Inhibitorji trpc6 |
AU2018393409A1 (en) * | 2017-12-26 | 2020-08-13 | Mediconns (Shanghai) Biopharmaceutical Co., Ltd | Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof |
UA128288C2 (uk) | 2018-03-08 | 2024-05-29 | Інсайт Корпорейшн | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> |
US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
RU2765721C1 (ru) * | 2018-06-15 | 2022-02-02 | Пфайзер Инк. | Агонисты glp-1 рецептора и их применение |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
EP3860987B1 (en) | 2018-10-02 | 2023-07-19 | Syngenta Participations Ag | Pesticidally active benzene- and azine-amide compounds |
BR112021007552A2 (pt) | 2018-10-22 | 2021-07-27 | Cadent Therapeutics, Inc. | formas cristalinas de moduladores de canal de potássio |
US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
KR20210106447A (ko) * | 2018-11-22 | 2021-08-30 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 효능제 및 그의 용도 |
EP3888848A4 (en) | 2018-11-26 | 2022-08-03 | Kyocera Corporation | GAS NOZZLE, METHOD OF MAKING A GAS NOZZLE AND PLASMA TREATMENT DEVICE |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
UY38623A (es) | 2019-03-29 | 2020-10-30 | Syngenta Crop Protection Ag | Compuestos de diazina-amida activos como pesticidas |
JOP20210272A1 (ar) | 2019-04-05 | 2023-01-30 | Syngenta Crop Protection Ag | مركبات دايازين - أميد نشطة بشكل مبيد للآفات |
JOP20210273A1 (ar) | 2019-04-11 | 2023-01-30 | Syngenta Crop Protection Ag | مركبات دايازين - أميد نشطة بشكل مبيد للآفات |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
CU20210083A7 (es) * | 2019-04-12 | 2022-05-11 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r |
EP4017851A1 (en) | 2019-08-23 | 2022-06-29 | Syngenta Crop Protection AG | Pesticidally active pyrazine-amide compounds |
US20220315568A1 (en) * | 2019-09-12 | 2022-10-06 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
US20230002348A1 (en) * | 2019-11-15 | 2023-01-05 | Ildong Pharmaceutical Co., Ltd. | GLP-1 Receptor Agonist and Use Thereof |
CA3171173A1 (en) * | 2020-03-18 | 2021-09-23 | Young Kwan Kim | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
JP2023537963A (ja) | 2020-08-13 | 2023-09-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 統合失調症に伴う認知機能障害に対する処置法 |
AU2021381323A1 (en) * | 2020-11-19 | 2023-06-22 | Cerecin Inc. | Radiopharmaceutical ketone and dual tracer imaging in alzheimer's disease, cognitive impairment, and other conditions of altered cerebral metabolism |
KR20230152654A (ko) | 2020-12-30 | 2023-11-03 | 타이라 바이오사이언시스, 인크. | 키나아제 억제제로서의 인다졸 화합물 |
JP2024524883A (ja) | 2021-06-09 | 2024-07-09 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性なジアジン-アミド化合物 |
EP4355729A1 (en) * | 2021-06-16 | 2024-04-24 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
WO2022266236A1 (en) | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
CA3236708A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
TW202421622A (zh) * | 2022-10-20 | 2024-06-01 | 南韓商東亞St股份有限公司 | 氮雜環丁烷基苯并㗁唑化合物及其等作為mer及axl抑制劑的用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
PE20030547A1 (es) | 2001-09-24 | 2003-08-18 | Bayer Corp | Derivados de imidazol para el tratamiento de la obesidad |
SI2527315T1 (sl) * | 2002-05-31 | 2014-06-30 | Proteotech Inc., | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen |
AU2003301436A1 (en) * | 2002-10-17 | 2004-05-04 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
GB0325287D0 (en) * | 2003-10-29 | 2003-12-03 | Merck Sharp & Dohme | Therapeutic agents |
JP4584990B2 (ja) | 2004-05-18 | 2010-11-24 | シェーリング コーポレイション | Pde4インヒビターとして有用な置換2−キノリル−オキサゾール |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
US20070072908A1 (en) | 2005-06-08 | 2007-03-29 | Japan Tobacco Inc. | Heterocyclic compounds |
WO2007076104A1 (en) * | 2005-12-23 | 2007-07-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US20100222353A1 (en) * | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
PE20091157A1 (es) | 2007-12-21 | 2009-09-03 | Astrazeneca Ab | Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 |
JP2011524917A (ja) | 2008-06-20 | 2011-09-08 | メタボレックス, インコーポレイテッド | アリールgpr119作動薬およびその使用 |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
NZ596078A (en) * | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
CA2772714C (en) * | 2009-09-03 | 2017-09-26 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
CN102498091B (zh) | 2009-09-16 | 2014-03-05 | 安斯泰来制药株式会社 | 甘氨酸化合物 |
AU2011253058A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
AU2011253143A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
MX2012013127A (es) | 2010-05-13 | 2012-11-30 | Amgen Inc | Compuestos heteroariloxiheterociclilo como inhibidores pde10. |
KR101564806B1 (ko) * | 2010-05-13 | 2015-10-30 | 암젠 인크 | Pde10 저해제로서 유용한 질소 헤테로시클릭 화합물 |
UY34858A (es) | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
-
2011
- 2011-05-11 KR KR1020127032541A patent/KR101564806B1/ko not_active IP Right Cessation
- 2011-05-11 EA EA201291236A patent/EA201291236A1/ru unknown
- 2011-05-11 CN CN201180034741.6A patent/CN103221404B/zh not_active Expired - Fee Related
- 2011-05-11 EP EP11721618A patent/EP2569300A1/en not_active Withdrawn
- 2011-05-11 WO PCT/US2011/036148 patent/WO2011143365A1/en active Application Filing
- 2011-05-11 MA MA35440A patent/MA34300B1/fr unknown
- 2011-05-11 NZ NZ603876A patent/NZ603876A/en not_active IP Right Cessation
- 2011-05-11 SG SG2012082939A patent/SG185515A1/en unknown
- 2011-05-11 BR BR112012029026A patent/BR112012029026A2/pt not_active Application Discontinuation
- 2011-05-11 CA CA2798490A patent/CA2798490A1/en not_active Abandoned
- 2011-05-11 MX MX2012013130A patent/MX2012013130A/es unknown
- 2011-05-11 US US13/105,860 patent/US8957073B2/en active Active
- 2011-05-11 PE PE2012002159A patent/PE20130576A1/es not_active Application Discontinuation
- 2011-05-11 JP JP2013510285A patent/JP5702855B2/ja not_active Expired - Fee Related
- 2011-05-11 AU AU2011253057A patent/AU2011253057B2/en not_active Ceased
- 2011-05-12 UY UY0001033382A patent/UY33382A/es not_active Application Discontinuation
- 2011-05-13 AR ARP110101668A patent/AR081627A1/es unknown
- 2011-05-13 TW TW100116952A patent/TW201206902A/zh unknown
- 2011-11-05 UA UAA201214182A patent/UA109438C2/uk unknown
-
2012
- 2012-11-06 IL IL222898A patent/IL222898A/en not_active IP Right Cessation
- 2012-11-07 TN TNP2012000530A patent/TN2012000530A1/en unknown
- 2012-11-12 ZA ZA2012/08510A patent/ZA201208510B/en unknown
- 2012-11-13 CL CL2012003178A patent/CL2012003178A1/es unknown
- 2012-11-15 CO CO12207172A patent/CO6630189A2/es active IP Right Grant
- 2012-12-13 CR CR20120635A patent/CR20120635A/es unknown
-
2014
- 2014-04-01 US US14/242,432 patent/US20140213572A1/en not_active Abandoned
-
2015
- 2015-12-17 US US14/973,491 patent/US9718803B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MA34300B1 (fr) | 2013-06-01 |
ZA201208510B (en) | 2017-11-29 |
US9718803B2 (en) | 2017-08-01 |
NZ603876A (en) | 2015-02-27 |
CA2798490A1 (en) | 2011-11-17 |
AR081627A1 (es) | 2012-10-10 |
BR112012029026A2 (pt) | 2016-08-02 |
SG185515A1 (en) | 2012-12-28 |
US8957073B2 (en) | 2015-02-17 |
WO2011143365A1 (en) | 2011-11-17 |
PE20130576A1 (es) | 2013-05-19 |
AU2011253057B2 (en) | 2014-11-20 |
KR101564806B1 (ko) | 2015-10-30 |
TW201206902A (en) | 2012-02-16 |
US20160102075A1 (en) | 2016-04-14 |
EP2569300A1 (en) | 2013-03-20 |
CL2012003178A1 (es) | 2013-07-05 |
IL222898A0 (en) | 2012-12-31 |
KR20130065666A (ko) | 2013-06-19 |
CN103221404A (zh) | 2013-07-24 |
TN2012000530A1 (en) | 2014-04-01 |
IL222898A (en) | 2015-11-30 |
US20110306587A1 (en) | 2011-12-15 |
UY33382A (es) | 2011-10-31 |
MX2012013130A (es) | 2013-04-11 |
CO6630189A2 (es) | 2013-03-01 |
CN103221404B (zh) | 2015-12-16 |
JP5702855B2 (ja) | 2015-04-15 |
EA201291236A1 (ru) | 2013-11-29 |
US20140213572A1 (en) | 2014-07-31 |
AU2011253057A1 (en) | 2012-11-29 |
JP2013526536A (ja) | 2013-06-24 |
UA109438C2 (uk) | 2015-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20120635A (es) | Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10 | |
UY34301A (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit | |
CR20120565A (es) | Indoles | |
PH12016500676A1 (en) | Pyrimidine fgfr4 inhibitors | |
UY34300A (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit | |
CR20130349A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III | |
UY34051A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
CR20120641A (es) | Compuestos macrocìclicos como inhibidores de quinasa trk | |
UY34393A (es) | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia | |
CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
CR20120295A (es) | Triazolopiridinas | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
UY34092A (es) | Nuevos compuestos como inhibidores de jak | |
CL2012002979A1 (es) | Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona. | |
CR20130045A (es) | Compuestos terapéuticos | |
UY34352A (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
CR20120297A (es) | Espironucleósidos uracílicos oxetánicos | |
UY34523A (es) | Derivados de betulina | |
UY33929A (es) | Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas | |
CR20120417A (es) | Inhibidores de virus flaviviridae | |
UY34654A (es) | Inhibidores de la beta-secretasa | |
CR20120113A (es) | (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer |